DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.

Yuechen LiuZhenkang LiJinchao ZhangWei LiuShenyuan GuanYizhi ZhanYuan FangYong-Sheng Li Haijun Deng Zhiyong Shen

Published in: British journal of cancer (2024)

Our work uncovers a novel function of DYNLL1 in orchestrating cell cycle to promote HCC development and suggests a potential synergy of CDK4/6 inhibitor and sorafenib for the treatment of HCC patients, especially those with increased DYNLL1.

Keyphrases

cell cycle
cell proliferation
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
patient reported outcomes
risk assessment